Doctors at Cambridge University have done a three-year trial of a drug called alemtuzumab on over 300 MS patients.
Those given the drug,a synthetic antibody developed at Cambridge 30 years ago, were 74% less likely to relapse, were 71% less likely to be disabled in three years time,but also showed fewer signs of disability.
The drug also seemed to promote brain repairs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment